Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy
Conditions
Interventions
Sarilumab
Placebo (for sarilumab)
+2 more
Locations
262
United States
Investigational Site Number 840070
Anniston, Alabama, United States
Investigational Site Number 840004
Birmingham, Alabama, United States
Investigational Site Number 840072
Gilbert, Arizona, United States
Investigational Site Number 840029
Beverly Hills, California, United States
Investigational Site Number 840007
Palm Desert, California, United States
Investigational Site Number 840008
San Francisco, California, United States
Start Date
March 1, 2010
Primary Completion Date
October 1, 2013
Completion Date
October 1, 2013
Last Updated
June 28, 2017
NCT07536529
NCT06329401
NCT07048197
NCT07484243
NCT06647069
NCT06841562
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions